FDA approves Lucamzi biosimilar to Lucentis
The FDA approved Lucamzi, a biosimilar to Lucentis.
Story updates
02:40:42 PM UTC
SquawkNews
Xbrane Biopharma AB received FDA approval for Lucamzi (ranibizumab-blrz), a biosimilar to Lucentis, and is preparing a US launch in 2027 with partners.Material DetailsContext by AI AnalystThis is a late-stage regulatory milestone in Xbrane’s strategy to commercialize ophthalmology biosimilars. Next…